Inhaled calcium salts inhibit tobacco smoke-induced inflammation by modulating expression of chemokines and cytokines

Publication date: Available online 22 October 2018Source: Pulmonary Pharmacology &TherapeuticsAuthor(s): Paulette W. Andreotta, Steve Arold, Jennifer Kenyon, Diane Spicer, Paul Woodman, Elizabeth Berry, Tim Brogan, Sophanna Kong, Pamela Okerholm, Vince Russell, Robert W. Clarke, David L. HavaAbstractTobacco smoke-induced lung inflammation in patients with chronic obstructive pulmonary disease (COPD) worsens with disease progression and acute exacerbations caused by respiratory infections. Chronic therapies to manage COPD center on bronchodilators to improve lung function and inhaled corticosteroids (ICS) to help reduce the risk of exacerbations. Novel therapies are needed that reduce the underlying inflammation associated with COPD and the inflammation resulting from respiratory infections that worsen disease. The lung is lined with airway surface liquid (ASL), a rheologically active material that provides an innate defense for the airway against inhaled particulate and is continuously cleared from the airways by mucociliary clearance. The rheological properties of the ASL can be altered by changes in airway hydration and by cations, such as calcium, that interact with electronegative glycoproteins. The effect of inhaled salts on inflammation resulting from tobacco smoke exposure was studied to determine if cations could be used to alter the properties of the ASL and reduce inflammation. Inhaled calcium salts, but not sodium or magnesium salts, reduced cellular inflammati...
Source: Pulmonary Pharmacology and Therapeutics - Category: Respiratory Medicine Source Type: research

Related Links:

ConclusionsThese findings suggest that triple therapy can potentially be the best option for stable COPD patients in terms of reducing exacerbation and all-cause mortality.
Source: PLoS Medicine - Category: Internal Medicine Authors: Source Type: research
Condition:   Chronic Obstructive Pulmonary Disease Interventions:   Drug: Methylprednisolone;   Drug: Placebos Sponsor:   Versailles Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractThe current recommendations for the treatment of chronic obstructive pulmonary disease (COPD) are pushing towards triple combination therapy based on the combination of an inhaled corticosteroid (ICS) associated with two bronchodilator agents. However, dual bronchodilation remains the cornerstone for the treatment of most COPD patients. Combining a long-acting β2 adrenoceptor agonist (LABA) with a long-acting muscarinic antagonist (LAMA) induces appreciable synergistic bronchorelaxant effect in human airways, especially when the medications are combined at isoeffective concentrations. Thus, each LABA/LAMA comb...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
ConclusionsPotentially inappropriate ICS use is common among patients with and without airflow obstruction who are diagnosed with COPD. We identified patient comorbidities and patterns of healthcare utilization that increase the likelihood of ICS use that could be targeted for system-level de-implementation interventions.
Source: Journal of General Internal Medicine - Category: Internal Medicine Source Type: research
Conclusion The prevalence of drug-related problems among the  studied COPD patients was high. Pharmacists can have an important role in addressing the problems and optimizing the safety and effectiveness of therapies for hospitalized COPD patients.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research
AbstractWixela® Inhub® is the first therapeutically equivalent, substitutable generic version of Advair Diskus® (fluticasone propionate/salmeterol) approved for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in the USA. Wixela Inhub combines the inhaled corticosteroid fluticasone propionate and the long-acting β2-adrenoceptor agonist salmeterol in a single dry-powder inhaler. Each drug has a different mechanism of action, targeting different and complementary aspects of the pathophysiology of asthma and COPD. The in vitro performance of Wixela Inhub is comparable to that of Advair...
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
Guidelines recommend that treatment with a long-acting β2 agonist (LABA), a long-acting muscarinic antagonist (LAMA), and inhaled corticosteroids (ICS), i.e. triple therapy, is reserved for a select group of symp...
Source: Respiratory Research - Category: Respiratory Medicine Authors: Tags: Review Source Type: research
Conclusions: Among patients with asthma-COPD overlap, LABA is associated with decreased risk of myocardial infarction; and the combination therapy of ICS/LABA appears to reduce the risk of death or hospitalization. More studies of quality data and larger number of patients are needed.REGISTRATION: PROSPERO (CRD42018090863). PMID: 31668101 [PubMed - as supplied by publisher]
Source: Journal of Asthma - Category: Respiratory Medicine Tags: J Asthma Source Type: research
Children with persistent asthma have loss of airway function despite chronic corticosteroid therapy. Those with severe disease may experience severe airway obstruction over time. It remains unclear whether treatment with immune-modulating agents, such as biologic agents, attenuates airway remodeling.
Source: Annals of Allergy, Asthma and Immunology - Category: Allergy & Immunology Authors: Source Type: research
Authors: Cheng WC, Liao WC, Wu BR, Chen CY, Shen MF, Chen WC, Hsia TC, Tu CY, Chen CH, Hsu WH Abstract Background: According to several phase III studies, tiotropium [a long-acting muscarinic antagonist (LAMA)] is a well-tolerated add-on therapy to inhaled corticosteroids (ICS) for asthmatics with or without the addition of long-acting beta2-agonists (LABAs). However, real-world studies based on clinical phenotypes to predict the long-term need of tiotropium as an add-on therapy for asthmatics are limited. Methods: This is a retrospective study conducted at a single medical center in Taiwan from July 2016 to Ju...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research
More News: Calcium | Chronic Obstructive Pulmonary | Corticosteroid Therapy | Drugs & Pharmacology | Magnesium | Respiratory Medicine | Smokers | Sodium